Global Plasma-derived Medicinal Products Market Research Report 2023

Plasma-derived medicinal products (PDMPs) are industrially manufactured from human plasma by pharmaceutical companies. Plasma is the liquid part of blood and it can be collected through specific procedures called plasmapheresis or obtained by the separation from the other components through physical means (centrifugation). PDMPs play a key, and sometimes non-replaceable, role in the treatment of many acute and chronic clinical conditions.

According to Researcher's new survey, global Plasma-derived Medicinal Products market is projected to reach US$ 47160 million in 2029, increasing from US$ 28320 million in 2022, with the CAGR of 7.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Plasma-derived Medicinal Products market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Plasma-derived Medicinal Products market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Takeda

CSL

Grifols

Octapharma

Kedrion

LFB Group

Biotest

BPL

Shanghai RAAS

China Biologic Products

Hualan Biological Engineering Inc.

Beijing Tiantan Biological Products Corp

Pacific Shuanglin

Boya Bio-Pharmaceutical

Paisi Feike Biology Pharmacy Co., Ltd.

Xinjiang Deyuan Bioengineering

Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Shenzhen Weiguang

Shanxi Kangbao

Nanyue Biopharming Corporation Ltd



Segment by Type


Immunoglobulins

Coagulation Factor Concentrates

Other



Segment by Application


Emergency Care

Epidemic Diseasae

Immune System Disorder

Antibody Deficiency

Coagulation Disorder

Others


Consumption by Region


North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

The Plasma-derived Medicinal Products report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Manufacturers’ Competition Patterns

Chapter 3: Country Level Sales Analysis

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6: Manufacturers’ Outline

Chapter 7: Industry Chain, Market Channel and Customer Analysis

Chapter 8: Market Opportunities and Challenges

Chapter 9: Market Conclusions

Chapter 10: Research Methodology and Data Source